NEW YORK (GenomeWeb News) – Illumina said today that its board of directors has approved a two-for-one stock split that will be effected in the form of a stock dividend.
 
The stock split is subject to shareholders approving an increase in the number of authorized shares of Illumina’s common stock from 120 million to 500 million. A special meeting is scheduled to take place on Sept. 9, at which time shareholders of record as of July 28 will be entitled to vote on the proposed amendment.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.